Zacks Investment Research on MSN

FDA expands MRK & PFE's Keytruda-Padcev combo use in bladder cancer

Merck MRK announced that the FDA has approved its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), and its subcutaneous ...
Hosted on MSN

MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate

Merck MRK and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III HERTHENA-Breast04 study evaluating their investigational HER3-directed DXd antibody-drug conjugate (ADC) ...
Nasdaq

MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug

Merck MRK and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III IDeate-Esophageal01 study evaluating their B7-H3 directed DXd antibody-drug conjugate (ADC), ifinatamab ...
Benzinga.com

Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study

On Wednesday, Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for ...
Newsable Asianet News on MSN

MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership

Merck cited business reasons for the discontinuation of the investigational drug.